Effects of pioglitazone and insulin on tight glycaemic control assessed by the continuous glucose monitoring system: A monocentric, parallel-cohort study

Clinical Drug Investigation

Volumn 25, Issue 5, 2005, Pages 347-352

  Jung, Wolfgang ^a   Jung, Sigrun ^a,b  

^a Hunsrück Diabetic Centre   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; SULFONYLUREA DERIVATIVE;

ADIPOCYTE; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTINUOUS GLUCOSE MONITORING SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN PUMP; INSULIN RESISTANCE; INSULIN TREATMENT; LIPID METABOLISM; LONG TERM CARE; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PARALLEL DESIGN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; RISK FACTOR; RISK REDUCTION; SELF MONITORING;

EID: 20444379967     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525050-00008     Document Type: Article

References (21)

1. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
2. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type II diabetes (UKPDS 33). Lancet 1998; 352: 837-53
3. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type II diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258): 405-12
4. 1c: a marker for complications of type II diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med 2003; 41 (9): 1182-90
5. Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med 1998; 15: 188-93
6. 1c. IOEZ Study Group. Diabetes Care 2000; 23: 1236-41
7. Shaw JE, Hodge AM, de Courten M, et al. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999; 42 (9): 1050-4
8. Lefebre PI, Scheen AJ. The postprandial state and risk of cardiovascular disease. Diabet Med 1998; 15 Suppl. 4: S63-8
9. Diamant M, Heine RJ. Thiazolidinediones in type II diabetes mellitus: current clinical evidence. Drugs 2003; 63 (13): 1373-405
10. Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type II diabetes mellitus. Coron Artery Dis 2001; 12: 413-23
11. Genuth S. Insulin use in NIDDM. Diabetes Care 1990; 13 (12): 1240-64
12. Amin R, Ross K, Acerini CL, et al. Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: use of continuous glucose monitoring system. Diabetes Care 2003; 26 (3): 662-7
13. Aussedat B, Dupire-Angel M, Gifford R, et al. Interstitial glucose concentration and glycemia: implications for continuous subcutaneous glucose monitoring. Am J Physiol Endocrinol Metab 2000; 278 (4): E716-28
14. Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 2001; 24 (12): 2030-4
15. Gross TM, Bode BW, Einhorn D, et al. Performance evaluation of the Mini Med continuous glucose monitoring system during patient home use. Diabetes Technol Ther 2000; 2 (1): 49-56
16. Kerr D. Continuous blood glucose monitoring: detection and prevention of hypoglycemia. Int J Clin Pract Suppl 2001; 123: 43-6
17. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995 Feb; 18 (2): 258-68
18. Wei M, Gaskill SP, Haffner SM, et al. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998 Jul; 21 (7): 1167-72
19. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004; 21: 568-76
20. Campbell IW. Long-term glycemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004; 58 (2): 192-200
21. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type II diabetes. Diabetes Care 2000; 23: 1605-11